$Eyenovia(EYEN.US)$Eyenovia (NASDAQ:EYEN) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by 35.29 percent. This is a 53.33 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $4.993 thousand which missed the analyst consensus estimate of $816.667 thousand by 99.39 percent.
$Eyenovia(EYEN.US)$Reuters· just Eyenovia Inc - Requested Meeting With FDA to Discuss Validation of the Gen-2 Dispenser, Which We Anticipate Will Occur This Summer
$Eyenovia(EYEN.US)$Well im taking this for a earnings spin! Hehehe! Wish me luck! I know that next Q will probably be much better because of some things not yet settled? But i really like it and if my earnings spin crashes? Well no harm because ive traded it before and i like it! So ill just swing it! Hehehe! NFA
$Eyenovia(EYEN.US)$Ok i will make you a deal! If you break 1.00? Whether that be today or soon. I will buy more! Even if i sell my whole position, ill buy right back at a buck! I mean thats a pretty good deal for you? Hehehe
$Eyenovia(EYEN.US)$Eyenovia Provides Clinical and Scientific Update On FDA-Approved Products Mydcombi And Clobetasol Propionate Ophthalmic Suspension Benzinga· 1 min ago Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8μL spray per eye) Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalmic suspensions to be dispensed with the O...
104681729 : 還不跑等警察來捉嗎?